Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Journal of biological engineering·2026

Same author

Linker Chemistry in Radiopharmaceutical Design.

Bioconjugate chemistry·2026

Same author

Fractionation gives therapeutic benefit in animal model of [<sup>177</sup>Lu]Lu-PSMA-617 therapy of prostate cancer.

EJNMMI research·2026

Same author

Tumour accumulation of anti-carcinoembryonic antigen affibody-albumin-binding domain fusion depends on domains' order.

International journal of biological macromolecules·2026

Same author

The Use of Glycine-Containing Peptide-Based Chelators for Labeling with <sup>99m</sup>Tc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1.

Molecular pharmaceutics·2026

Same author

Efficient <sup>68</sup>Ga Labeling of a B7-H3-Targeting Affibody Molecule via Acyclic Tris(hydroxypyridinone) Chelator: Effects on Biodistribution in a Preclinical Model.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Feb 27, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Pretargeted Imaging and Therapy.

Mohamed Altai¹, Rosemery Membreno^2,3,4, Brendon Cook^2,3,4

¹Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|July 9, 2017

Summary

This summary is machine-generated.

In vivo pretargeting uses separate administration of targeting vectors and radioisotopes for improved nuclear imaging and therapy. This approach enhances tumor targeting while reducing radioactivity in healthy tissues.

Keywords:

biotin bispecific antibody click chemistry multistep targeting pretargeting streptavidin

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Feb 27, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Area of Science:

Biomedical imaging
Radiopharmaceutical therapy
Molecular targeting

Background:

Antibody-based targeting offers high specificity but faces pharmacokinetic challenges like prolonged circulation and off-target accumulation.
In vivo pretargeting aims to overcome these limitations by separating the administration of targeting agents and radioisotopes.
This strategy allows for the use of short-lived radionuclides, improving imaging and therapeutic efficacy.

Purpose of the Study:

To provide a concise review of the four main mechanistic approaches to in vivo pretargeting.
To highlight the advantages of pretargeting in nuclear imaging and therapy.
To survey strategies based on streptavidin-biotin, bispecific antibodies, oligonucleotide complementarity, and click chemistry.

Main Methods:

Review of existing literature on in vivo pretargeting strategies.
Categorization of pretargeting methods into four distinct mechanistic approaches.
Analysis of the principles and applications of each pretargeting strategy.

Main Results:

Pretargeting significantly reduces radioisotope circulation time and off-target uptake in healthy tissues.
It enables the effective use of short-lived radionuclides, enhancing imaging resolution and therapeutic index.
Four primary pretargeting mechanisms were identified: streptavidin-biotin, bispecific antibodies, oligonucleotide pairing, and bioorthogonal click chemistry.

Conclusions:

In vivo pretargeting is a powerful strategy to enhance the clinical utility of radiolabeled antibodies for imaging and therapy.
The reviewed mechanistic approaches offer diverse solutions for optimizing radioisotope delivery and minimizing systemic exposure.
Further development of these pretargeting platforms holds significant promise for advancing precision oncology.